Therapeutic Programs

therapeutic programs

Pipeline

ProgramStage of Development

Indication

Target

Discovery

Lead Optimization

IND Enabling

Phase 1

Phase 2

Phase 3

Anticipated Milestones

Oncology

Metastatic Castration-Resistant Prostate Cancer

ARV-110AR
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
  • Preliminary Data 2H19
  • Full Ph 1 data 1H20
Next Generation DegraderAR
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
AR Variant DegraderAR-V7
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3

Metastatic ER+ Breast Cancer

ARV-471ER
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
  • IND Filing Q2 19
  • Initiate Ph 1 Q3 19
  • Preliminary Data 2020

Additional Oncology Indications

CRC, NSCLCUndisclosed
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
Central Nervous System

Tauopathies

MultipleTau
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
  • Preclinical data 2H19

    Synucleinopathies

    Multipleα-Synuclein
    DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3

    Other neuroscience indications

    Unspecified
    DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3